Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy

NCT05125068 is registered in ClinicalTrials.gov with Eledon Pharmaceuticals as lead sponsor.

NCT NCT05125068
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05125068 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy
Lead sponsor
Eledon Pharmaceuticals
Phase
Phase 2
Overall status
Terminated
Start date
March 21, 2022
Completion date
July 31, 2023
Enrollment
24 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy, igan